clinical research studies near me

Moscow, Russia

• Actively Recruiting

• NCI CTEP IAM User Access Update
• Coronavirus Guidance
• Biomarker Resources
• Career Development Opportunities
• Childhood Cancer Resources
• CIRB/Study Participant Protections
• Conflict of Interest Policy
• Funding Opportunities
• Investigator’s Handbook
• Radiopharmaceutical Development Initiative
• Registration and Credential Repository
• Adverse Events/CTCAE
• Agent/Drug Management
• Ancillary/Correlative and Biomarker Studies
• CDE/Data Policies/CDUS/DMU
• Informed Consent
• LOIs/Concepts
• OEWG Information & Timeline Reports
• Project Team Member Applications
• Protocol Development Tools
• CTEP Agreements and Agents
• Guidelines for Collaborations with Industry
• Experimental Therapeutics Clinical Trials Network (ETCTN)
• National Clinical Trials Network (NCTN)
• Pediatric Early Phase Clinical Trials Network (PEP-CTN)
• NCI Drug Development Project Teams
• The NCI Formulary
• Map & Directions
• Organization Chart
• Staff Directory

CTEP Branches and Offices

Investigational drug branch (idb), idb oversees an innovative early therapeutics clinical research program., idb collaborates with academia and industry through an nci-funded program to carry out the clinical evaluation of novel anti-cancer agents..

Two programs run in sequence to manage a portfolio of partnerships between NCI and Pharma:

• NExT is the program in the NCI Developmental Therapeutics Program that selects agents for NCI-sponsored pre-clinical and clinical development
• The Experimental Therapeutics Clinical Trials Network (ETCTN) is the clinical trials network administered through the IDB that performs clinical studies of the agents that are approved through NExT. Dr. Percy Ivy is the Program Director for the ETCTN and Kim Witherspoon is the Senior Program Specialist.

In these partnerships, NCI:

• Assumes the regulatory responsibility for the ETCTN clinical trials (IND holder)
• Sponsors clinical trials to advance the development of these NCI-IND agents in the ETCTN.

IDB physicians:

• Work with ETCTN investigators and pharma partners to formulate the clinical development plans for NCI-IND agents, including review and prioritization of clinical trial proposals (Letter of Intent (LOI))
• Monitor ETCTN clinical trials for safety and efficacy
• Investigate and prepare reports concerning adverse events (AEs) for the NCI-IND agents.
• Work closely with the Investigational Drug Steering Committee and its Task Forces to increase the transparency and openness of the trial design and prioritization process

IDB is comprised of the following Sections and agent portfolios:

For academic investigators with new clinical trial proposals interested in submitting an unsolicited LOI, please contact the IDB physician in charge of the appropriate drug portfolio for further discussions. This step will help to ensure the proposed LOI will not be duplicative and is written in an effective manner that will increase its likelihood of acceptance and funding by CTEP. The IDB physicians assigned to each agent can be found under CTEP Agents and Active Agreements .

IDB staff also have leadership roles in three Cancer Moonshot programs.

PDXNet is a network of four PDX Development and Trial Centers(U54) and one PDXNet Data Commons and Coordinating Center (U24) focusing on preclinical research on NCI-IND agents in PDX models to lead to clinical translation in the ETCTN. Dr. Jeff Moscow is the Program Director and Kim Witherspoon is the Senior Program Specialist.

The Drug Resistance and Sensitivity Network (DRSN) is a network of four Drug Resistance and Sensitivity Centers (U54) that examine issues in drug resistance and drug sensitivity that can lead to clinical translation in the ETCTN as well as in other clinical trials. Dr. Austin Doyle is the Program Director and Kim Witherspoon is the Senior Program Specialist.

The network of four Cancer Immune Monitoring and Analysis Centers (CIMACs; U24) and one Cancer Immunologic Data Commons (CIDC; U24) is creating a national resource for providing validated, standardized and harmonized biomarker assays for national clinical trials. Dr. Helen Chen is Co-Leader of this effort and Dr. Min Song is a Program Director.

Institute for Applied Medical Research

A pilot plant "Pul-Sar" in Dubna (Special Economic Zone "Dubna"

"Russian Medical School" is an educational institution for postgraduate medical education

If you have any questions or suggestions?

Please contact us

+7 (968) 408 42 - 69

[email protected]

Developments

We cooperate with:

• N.N. Priorov Central Institute of Trauma Surgery (development of the newest methods of hemostasis during spine surgeries)
• M.F. Vladimirsky Moscow Regional Clinical Research Institute (clinical studies of endoscopic methods of hemostasis)
• N.V. Sklifosovsky Research Institute of Emergency Medicine (development of methods of emergency gastroenterological care)
• A.N. Rychikh Scientific Research Center for Coloproctology (colorectal surgery, endoscopy)
• Sechenov Moscow State Medical University
• Pirogov Russian National Research Medical University
• Pavlov Russian State Medical University
• Russian Society of Surgeons
• Children’s City Clinical Hospital named after Z.A. Bashlyaeva

Press service

Stay informed

October 14 21

Dubna, Ulitsa Programmistov 4, building 6 Special Economic Zone “Dubna”

• State registration certificate
• Certificate of registration with the tax authority
• Statute IAMR

Clinical trials

The Moscow Center for Diagnostics & Telemedicine is certified by the Moscow Health Care Department to conduct clinical trials as per the Unified Register of Organizations Authorized to Conduct Trials (Testing) of Medical Devices for the Purpose of their Registration on the Territory of the  EAEU , the Roszdravnadzor Register of Medical Organizations Conducting Clinical Trials of Medical Devices , the legislation of the Russian Federation, international documents, the Charter and the Policy on Clinical Trials.

Please send an  application  in  arbitrary form and your questions to  [email protected]

Expertise accumulated during the Computer Vision Moscow Experiment

The Center develops regulatory technical documents related to “Artificial Intelligence in Healthcare” (a series of national standards)

The Computer Vision Moscow Experiment aggregated and tested the reference data sets

The Clinical Trials Sector operates on the basis of the Center

A methodology of clinical trials was developed and tested in line with the draft national standard for clinical assessment

compliance assessment of a medical device to obtain a Marketing Authorization from Roszdravnadzor based on the GCP principles

software as a medical device

is to study the functional properties, efficiency and safety of a medical device in accordance with its use case scenarios as specified in the manufacturer's documentation

by analysing and evaluating data in accordance with the program of clinical trials

Invitro Clinical Research

INVITRO Clinical Research has supported clinical study teams at pharma companies and CROs facing the challenges of recruiting study subjects

www.invitro-cr.com

• General Information
• Quality Assurance
• Patient service
• Project Management
• Request for Proposal

Legal Disclaimer

• Privacy Policy
• Cookie Policy

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Published: 19 December 2017

The evidence framework for precision cancer medicine

• Jeffrey A. Moscow 1 ,
• Tito Fojo 2 , 3 &
• Richard L. Schilsky 4  

Nature Reviews Clinical Oncology volume  15 ,  pages 183–192 ( 2018 ) Cite this article

5618 Accesses

111 Citations

14 Altmetric

Metrics details

• Cancer genetics
• Cancer genomics
• Clinical trials
• Personalized medicine
• Targeted therapies

Precision cancer medicine (PCM) is a concept in which oncologists increasingly strive to tailor the use of targeted therapies in order to match the complexity of the cancer genome. This approach contradicts the historical framework used to support oncology practice that requires evidence from randomized controlled trials in order to change standards of care. This contrast demonstrates the irony of PCM: the therapies themselves are more precise than standard cytotoxic agents, although the clinical evidence supporting the benefits of these therapies is often considerably less precise. Nevertheless, the implementation of PCM should still be based on a framework of evidence-based development that supports clinical decision-making; this approach should not be simple off-label prescription of drugs following sequencing of a tumour biopsy sample. The clinical validation of increasingly complex diagnostic tests, the development of novel methods of evaluating efficacy, and the re-assessment of the standards of evidence sufficient to demonstrate the benefit of precision cancer therapies are all needed before PCM becomes the standard of care for patients with tumours harbouring genomic abnormalities of uncertain clinical significance.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Buy this article

• Purchase on Springer Link
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Delivering precision oncology to patients with cancer

The coming decade in precision oncology: six riddles

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

Ottmann, O. G. et al . A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 , 1965–1971 (2002).

Article   CAS   Google Scholar  

Sawyers, C. L. et al . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 , 3530–3539 (2002).

O'Brien, S. G. et al . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 , 994–1004 (2003).

Perez, E. A. et al . Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29 , 3366–3373 (2011).

Perez, E. A. et al . Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J. Clin. Oncol. 32 , 3744–3752 (2014).

Rosell, R. et al . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 , 239–246 (2012).

Fukuoka, M. et al . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29 , 2866–2874 (2011).

Hauschild, A. et al . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 , 358–365 (2012).

Hyman, D. M. et al . Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373 , 726–736 (2015).

Le Tourneau, C. et al . Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials. J. Natl Cancer Inst. 108 , djv362 (2016).

Article   Google Scholar  

Meric-Bernstam, F. et al . A decision support framework for genomically informed investigational cancer therapy. J. Natl Cancer Inst. 107 , djv098 (2015).

Sukhai, M. A. et al . A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet. Med. 18 , 128–136 (2016).

Papaemmanuil, E., Dohner, H. & Campbell, P. J. Genomic classification in acute myeloid leukemia. N. Engl. J. Med. 375 , 900–901 (2016).

Klco, J. M. et al . Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25 , 379–392 (2014).

Levis, M. Midostaurin approved for FLT3-mutated AML. Blood 129 , 3403–3406 (2017).

Kris, M. G. et al . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 , 1998–2006 (2014).

Munoz, J., Schlette, E. & Kurzrock, R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J. Clin. Oncol. 31 , e351–352 (2013).

Peters, S., Michielin, O. & Zimmermann, S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J. Clin. Oncol. 31 , e341–e344 (2013).

Wagle, N. et al . Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4 , 546–553 (2014).

Prasad, V. Perspective: The precision-oncology illusion. Nature 537 , S63 (2016).

Tannock, I. F. & Hickman, J. A. Limits to personalized cancer medicine. N. Engl. J. Med. 375 , 1289–1294 (2016).

Tannock, I. F. & Hickman, J. A. Limits to precision cancer medicine. N. Engl. J. Med. 376 , 96–97 (2017).

PubMed   Google Scholar  

Iyer, G. et al . Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31 , 3133–3140 (2013).

Radovich, M. et al . Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget 7 , 56491–56500 (2016).

Tsimberidou, A. M. et al . Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin. Cancer Res. 18 , 6373–6383 (2012).

Von Hoff, D. D. et al . Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28 , 4877–4883 (2010).

MacConaill, L. E. et al . Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J. Mol. Diagn. 16 , 660–672 (2014).

Hakenberg, J. et al . Integrating 400 million variants from 80,000 human samples with extensive annotations: towards a knowledge base to analyze disease cohorts. BMC Bioinformatics 17 , 24 (2016).

Uzilov, A. V. et al . Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 8 , 62 (2016).

ECOG-ACRIN Cancer Research Group. Executive summary: interim analysis of the NCI-MATCH trial. ECOG-ACRIN Cancer Research Group http://ecog-acrin.org/nci-match-eay131/interim-analysis (2016).

Marchione, M. Ultra-personal therapy: gene tumor boards guide cancer care. ABCNews http://abcnews.go.com/amp/Health/wireStory/ultra-personal-therapy-gene-tumor-boards-guide-cancer-50551995 (2017).

Chakradhar, S. Group mentality: determining if targeted treatments really work for cancer. Nat. Med. 22 , 222–224 (2016).

Wagle, N. et al . Response and acquired resistance to everolimus in anaplastic thyroid cancer. N. Engl. J. Med. 371 , 1426–1433 (2014).

Li, M. M. et al . Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19 , 4–23 (2017).

Hughes, K. S. et al . Identifying health information technology needs of oncologists to facilitate the adoption of genomic medicine: recommendations from the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. J. Clin. Oncol. 35 , 3153–3159 (2017).

Dienstmann, R., Rodon, J., Barretina, J. & Tabernero, J. Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol. 31 , 1874–1884 (2013).

Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31 , 1806–1814 (2013).

Macconaill, L. E. & Garraway, L. A. Clinical implications of the cancer genome. J. Clin. Oncol. 28 , 5219–5228 (2010).

Meador, C. B. et al . Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res. 20 , 2264–2275 (2014).

Nikanjam, M., Liu, S., Yang, J. & Kurzrock, R. Dosing three-drug combinations that include targeted anti-cancer agents: analysis of 37,763 patients. Oncologist 22 , 576–584 (2017).

Liu, S., Nikanjam, M. & Kurzrock, R. Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers. Oncotarget 7 , 11310–11320 (2016).

PubMed   PubMed Central   Google Scholar  

Schwaederle, M. et al . Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J. Clin. Oncol. 33 , 3817–3825 (2015).

Jardim, D. L. et al . Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J. Natl Cancer Inst. 107 , djv253 (2015).

Herbst, R. S. et al . Lung Master Protocol (Lung-MAP) — a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin. Cancer Res. 21 , 1514–1524 (2015).

LoRusso, P. M. et al . Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF -mutant metastatic melanoma: experience of the SU2C/MRA melanoma dream team. Mol. Cancer Ther. 14 , 1962–1971 (2015).

Bashaw, E. D. & Fang, L. Clinical pharmacology and orphan drugs: an informational inventory 2006–2010. Clin. Pharmacol. Ther. 91 , 932–936 (2012).

U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. U.S. Food and Drug Administration https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm (2017).

Ritter, D. I. et al . Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med. 8 , 117 (2016).

Gee, A. W., Balogh, E., Patlak, M. & Nass, S. J. The drug development daradigm in oncology. Proceedings of a workshop . (The National Academies Press, 2017).

Google Scholar  

Lopez-Chavez, A. et al . Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J. Clin. Oncol. 33 , 1000–1007 (2015).

Meric-Bernstam, F. et al . Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J. Clin. Oncol. 33 , 2753–2762 (2015).

Le Tourneau, C. et al . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16 , 1324–1334 (2015).

Haslem, D. S. et al . A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J. Oncol. Pract. 13 , e108–e119 (2017).

Wheler, J. J. et al . Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76 , 3690–3701 (2016).

Massard, C. et al . High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7 , 586–595 (2017).

Download references

Author information

Authors and affiliations.

Jeffrey A. Moscow is at Room 5W524, National Cancer Institute Shady Grove, 9609 Medical Center Drive, Bethesda, Maryland 20892–9739, USA.,

Jeffrey A. Moscow

Tito Fojo is at the Division of Haematology Oncology, Department of Medicine, Columbia University, Herbert Irving Pavilion 9–936, New York, New York 10032, USA; and the James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA.,

and the James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA.,

Richard L. Schilsky is at the American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, Virginia 22314, USA.,

Richard L. Schilsky

You can also search for this author in PubMed   Google Scholar

Contributions

All authors made a substantial contribution to all aspects of the preparation of this manuscript.

Corresponding author

Correspondence to Jeffrey A. Moscow .

Ethics declarations

Competing interests.

The authors declare no competing financial interests.

Related links

Further information.

ClinGen, Clinical Genome resource

International Cancer Genome Consortium

Global Alliance for Genomics and Health

AACR Project GENIE

Pancreatic Cancer Action Network: Know Your Tumor

The Bladder Cancer Action Network Bladder Cancer Genomics Consortium

Multiple Myeloma Research Foundation COMMPASS registry

PowerPoint slides

Powerpoint slide for table 1, powerpoint slide for table 2, supplementary information.

Supplementary information S1 (table) (PDF 437 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Moscow, J., Fojo, T. & Schilsky, R. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 15 , 183–192 (2018). https://doi.org/10.1038/nrclinonc.2017.186

Download citation

Published : 19 December 2017

Issue Date : March 2018

DOI : https://doi.org/10.1038/nrclinonc.2017.186

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

Personalizing adjuvant therapy for patients with colorectal cancer.

• Jinlin Yang
• David J. Kerr

Nature Reviews Clinical Oncology (2024)

A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs

• Changwen Wang
• Hai-Kun Liu

npj Precision Oncology (2024)

Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

• Kathrin Heinrich
• Lisa Miller-Phillips
• C. Benedikt Westphalen

Journal of Cancer Research and Clinical Oncology (2023)

Consequences of aberrated DNA methylation in Colon Adenocarcinoma: a bioinformatic-based multi-approach

• Arash Moradi
• Milad Shahsavari
• Shahla Mohammad Ganji

BMC Genomic Data (2022)

Identifying tumor cells at the single-cell level using machine learning

• Artem Baranovskii
• Altuna Akalin

Genome Biology (2022)

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

• Earn $10 rewards on $40+
• Up to 50% off select vitamins & supplements
• Up to 60% off clearance
• Your Account
• Walgreens Cash Rewards
• Prescription Refills & Status
• Vaccination Records
• Order Status & History
• Buy It Again

Select a store

Home  > Health Services

Clinical Trials

Everyone's welcome to join a clinical trial—no experience required..

Featured clinical trials

Major depressive disorder

Learn more about a clinical study for adults diagnosed with depression.

Lung cancer screening

Help develop a test that detects lung cancer early, when more treatment options are available.

HIV prevention

Study to improve HIV prevention for Black women.

All clinical trials

Medical breakthroughs wouldn’t be possible without clinical trials..

By including people of various communities, ages, races, genders and ethnicities, researchers can better understand how people respond to treatments. This helps to ensure that medical advancements are safe, effective, and accessible, ultimately leading to more equitable healthcare for all.

Joining a clinical trial doesn’t mean you’ll be a guinea pig or receive low-quality care.

Patient care and safety is prioritized above all else. You’re able to stop participation at any time, and you’ll never be treated as a lab rat or guinea pig. Here are just a few of the additional benefits research participants experience by joining clinical trials:

Better understand your health & condition

Access to the latest treatments & technology

Condition-specific care from trusted sources

Directly contribute to medical breakthroughs

Do you have questions about clinical trials or want to share your participant story?

We want to hear from you! Email us at [email protected] or connect with us on any of the social channels below.

Note: This contact form is for general inquiries only. Do not use the form to share medical information or communicate about specific ongoing studies. Contact the research team directly if you have questions about a specific study.

Clinical trials are research studies that look at new ways to prevent, detect or treat diseases. They rely on human volunteers, known as participants , and aim to find out if a new medical approach is safe and effective. Clinical trials often test new drugs or new combinations of drugs, new surgical procedures or devices, or different ways to use existing treatments. Clinical trials can also test other aspects of care, such as ways to improve the quality of life for people with chronic conditions.

People of all ages, genders, races and ethnic groups can volunteer to participate, and all participants must qualify for a study before joining a clinical trial. Each clinical trial has specific eligibility criteria , which help identify appropriate participants and ensure their safety. Eligibility criteria consist of both inclusion criteria (required for participation) and exclusion criteria (which prevent participation). These criteria are based on factors such as age, gender, disease type and stage, treatment history and other medical conditions. Some studies look for patient volunteers who have a known health condition and can help improve understanding, diagnosis or treatment, while others need healthy volunteers who don’t have significant health problems and may be needed to help test new treatments.

Each clinical trial has a unique set of requirements and screening process. Before joining a trial, you’ll receive an informed consent form detailing the study’s purpose, duration, compensation, contact information, and required tests or procedures. The form also explains the study’s known benefits and risks and can help participants make an informed decision about whether to join a study. Study participation is a personal decision. The research team will be prepared to answer questions to help you fully understand what to expect before, during and after the study

• Phase 1 – Testing begins with a small group of people (typically 20–80) to help evaluate safety and identify side effects.
• Phase 2 – More people are included (typically 100–300) to determine effectiveness and continue evaluating safety.
• Phase 3 – The new drug or treatment is given to a larger group of people (typically 1,000–3,000) to help confirm effectiveness, monitor side effects and compare it with current treatments.
• Phase 4 – After a drug or device is approved by the FDA and made available to the public, researchers continue monitoring its safety and effectiveness in the general population.

A clinical trial sponsor is the person, institution, company or organization responsible for initiating, managing or financing the clinical trial. A study’s principal investigator (PI) , often a medical doctor, works closely with the clinical research coordinator (CRC) to lead the trial and help ensure compliance and safety. The PI and CRC typically work for the sponsor and leads a team of research staff that could include doctors , nurses , technicians and other healthcare professionals. Members of the research team regularly monitor participants’ health to determine the study’s safety and effectiveness.

Walgreens has partnered with trial sponsors and researchers to help make clinical trials more accessible. Browse our active clinical trials and select “Learn more” to see how you can get involved.

Insurance is generally not required to participate in a clinical trial.

Participants may be paid, but the amount varies based on the study. Some clinical trials will provide compensation for the time and effort involved with participation, and reimbursement for costs associated with research-related travel, such as parking fees or meals.  

Yes. You can decide to end your participation and withdraw at any time. Just tell the study researcher if you wish to stop being in the study. You don’t need to give a reason why you want to stop participating.

There are different types of clinical trials; they don’t always test medicine or include a placebo , which is a pill or substance that has no therapeutic effect. Placebos aren’t used in research if an effective treatment is already available or if the lack of effective therapy would put a person at risk. Participants will always be notified if a trial uses a placebo during the informed consent process .

Clinical trial participant privacy and confidentiality are protected by law. For example, trials that use or disclose a participant’s protected health information (PHI) for research purposes must be conducted in accordance with the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) . During the informed consent process, participants will receive information on personal information collected during the trial, how it will be used, who will have access to the information, and rights regarding personal information.

Factors like age, race and gender influence the risk and likelihood of developing a disease and responses to treatment. By including more diverse groups of people in clinical trials, we can better understand the therapy effectiveness and safety for the broader population.

Better understand how you can engage with clinical trials, no matter where you are in their health journey, from trusted sources.

National Institutes of Health: Clinical Research Trials and You

FDA: Clinical Trial Diversity

Patient Advocate Foundation: Education Resource Library

FDA: "Medical Device Clinical Trials" (video)

The Center for Information and Study on Clinical Research Participation: Education Center

NoiseFilter: "Clinical Trials: The Heart and Soul of Science" (video)

NoiseFilter: "Clinical Trials: Lights, Camera, Take Action!" (video)

University at Buffalo Clinical and Translational Science Institute: "Sofia Learns About Research" (children's activity book)

Walgreens Clinical Trials for sponsors: Clinical Trials for Healthcare Companies

https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics

https://www.nia.nih.gov/health/clinical-trials-and-studies/what-are-clinical-trials-and-studies

https://www.nhlbi.nih.gov/research/clinical-trials/participating

https://www.nih.gov/health-information/nih-clinical-research-trials-you/glossary-common-terms

https://clinicaltrials.gov/study-basics/learn-about-studies

https://clinicaltrials.gov/study-basics/glossary

https://www.hhs.gov/hipaa/for-professionals/special-topics/research/index.html

https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html

In a conversation with Ramita Tandon, Walgreens’ Chief Clinical Trials Officer, we explore the company’s cutting-edge strategies to maximize its expansive pharmacy network for clinical trials conducted at retail pharmacies. This interview illuminates the ways in which Walgreens integrates technological advancements and engagement tactics to revolutionize the process of enrolling participants and decentralizing clinical trials.

Collaborating with community partners, we design and build outreach and engagement activations to break down barriers e.g. the lack of awareness about trials, mistrust of research, and logistical obstacles that prevent equitable access across sub-groups.

The 2024 SCOPE Summit, a pivotal event in clinical trials, showcased innovative strategies to transform patient recruitment and trial conduct. At the forefront of these discussions was John Campbell, Head of Decentralized Trials for Walgreens, who shared profound insights

Less than two years after entering the clinical trials business, Walgreens has made strides in increasing diverse representation in pharmaceutical trials, according to Ramita Tandon, the company’s chief clinical trials officer. The retail pharmacy giant opened a clinical trials arm in June 2022 with the goal of diversifying trial participants, which have historically been overwhelmingly white and male.

Clinical trial recruitment has historically been centered in larger urban areas near established medical institutions, leaving out the nearly 61 million Americans that live in rural locations where healthcare access is limited. Walgreens is proud to be an industry leader in increasing access to clinical research across the country, and is committed to reaching vulnerable and marginalized populations that are often excluded from

Diverse participation in clinical trials is critically low. At this year’s Black Women’s Expo, Walgreens sponsorship centered on educating the community and sparking change for better health outcomes.

In this session at DIA, John Campbell, head of decentralized trials, Walgreens began with emphasizing that much of industry does not yet understand the role of pharmacy in clinical trials.

Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business. The company signed a deal with biotech startup Freenome to advance clinical trials of its blood-based tests for the early detection of cancer.

The commitment of pharmacy to address clinical trials has been a recurring topic this week. Craig Lipset was joined by Kendal K. Whitlock, MPH, Head of Digital Optimization, RWE Clinical Trials from Walgreens to discuss the state of the industry, commitment to the field, and progress to-date.

In the digital age, technology has become an important tool to improve involvement in clinical trials. Watch this discussion with Kendal Whitlock, Head of Digital Operations at Walgreens Boot Alliance

Walgreens Clinical Trials Events

Leveraging rich real world data (RWD), Walgreens delivered patient referrals that improve on the national averages of diverse participation, also demonstrating that our referrals are 20% more likely to enroll in study compared to other recruitment providers' referrals.

Walgreens leveraged rich and diverse real world data (RWD) and was able to deliver referrals that exceeded the targeted goal of our study partner by 23%, all within a two-week recruitment period.

Walgreens identified and engaged the right patients using our unparalleled RWD to enable a significant recruitment of Black/African American (17%) and Hispanic/Latino (19%) population in this clinical trial. These results are a significant improvement when compared to nationwide historical averages of clinical trial participation (as of 2020 of 8% and 11% respectively).

Walgreens leveraged their unparalleled real-world data insights to identify eligible patient populations within 20 miles of study sites.

Walgreens leveraged our unparalleled patient insights and community presence to identify and engage potential participants so efficiently that we outperformed other recruitment partners--64% of qualified referrals and 62% of randomized patients.

You're leaving Walgreens

Any information you provide will be subject to our partner’s privacy and security policies.

You're about to enter W en español

Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms

• Advanced Search
• See Studies by Topic
• See Studies on Map
• How to Search
• How to Use Search Results
• How to Find Results of Studies
• How to Read a Study Record

• Learn About Studies
• Other Sites About Studies
• Glossary of Common Site Terms

• Submit Studies to ClinicalTrials.gov PRS
• Why Should I Register and Submit Results?
• FDAAA 801 and the Final Rule
• How to Apply for a PRS Account
• How to Register Your Study
• How to Edit Your Study Record
• How to Submit Your Results
• Frequently Asked Questions
• Support Materials
• Training Materials

• Selected Publications
• Clinical Alerts and Advisories
• Trends, Charts, and Maps
• Downloading Content for Analysis

• ClinicalTrials.gov Background
• About the Results Database
• History, Policies, and Laws
• ClinicalTrials.gov Modernization
• Media/Press Resources
• Linking to This Site
• Terms and Conditions
• Search Results
• Study Record Detail

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)

• Study Details
• Tabular View
• Study Results

This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic PsO.

The study will consist of 24 weeks of administration of blinded study drug, divided into Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period 1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in Treatment Period 3.

Inclusion Criteria:

• Male or female adults
• PsO diagnosis for 6 months
• Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale of 0-5),
• Body Surface Area (BSA) involved with PsO greater than or equal to 10%

Exclusion Criteria:

• Forms of psoriasis other than PsO
• Drug induced psoriasis
• Positive QuantiFERON-tuberculosis (TB) Gold Test
• Presence of significant comorbid conditions
• Chemistry and hematology values outside protocol specified range
• Major systemic infections

• For Patients and Families
• For Researchers
• For Study Record Managers
• Customer Support
• Accessibility
• Viewers and Players
• Freedom of Information Act
• HHS Vulnerability Disclosure
• U.S. National Library of Medicine
• U.S. National Institutes of Health
• U.S. Department of Health and Human Services

Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies

Affiliations.

• 1 Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
• 2 Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (A.V.S., S.A.D., M.M.A., H.B.S.); and Department of Pharmacology, Institute of Pharmacy (A.V.S., S.A.D., A.A.K., A.A.I., A.S.N., A.A.L., V.N.C., V.V.T.) and Institute of Translational Medicine and Biotechnology (V.V.T., H.B.S.), I. M. Sechenov First Moscow State Medical University, Moscow, Russia [email protected].
• PMID: 34663683
• DOI: 10.1124/pharmrev.121.000317

Brain cancer is a formidable challenge for drug development, and drugs derived from many cutting-edge technologies are being tested in clinical trials. We manually characterized 981 clinical trials on brain tumors that were registered in ClinicalTrials.gov from 2010 to 2020. We identified 582 unique therapeutic entities targeting 581 unique drug targets and 557 unique treatment combinations involving drugs. We performed the classification of both the drugs and drug targets based on pharmacological and structural classifications. Our analysis demonstrates a large diversity of agents and targets. Currently, we identified 32 different pharmacological directions for therapies that are based on 42 structural classes of agents. Our analysis shows that kinase inhibitors, chemotherapeutic agents, and cancer vaccines are the three most common classes of agents identified in trials. Agents in clinical trials demonstrated uneven distribution in combination approaches; chemotherapy agents, proteasome inhibitors, and immune modulators frequently appeared in combinations, whereas kinase inhibitors, modified immune effector cells did not as was shown by combination networks and descriptive statistics. This analysis provides an extensive overview of the drug discovery field in brain cancer, shifts that have been happening in recent years, and challenges that are likely to come. SIGNIFICANCE STATEMENT: This review provides comprehensive quantitative analysis and discussion of the brain cancer drug discovery field, including classification of drug, targets, and therapies.

Copyright © 2021 by The Author(s).

Publication types

• Antineoplastic Agents*
• Brain Neoplasms* / drug therapy
• Drug Discovery
• Pharmaceutical Preparations*
• Proteasome Inhibitors
• Antineoplastic Agents
• Pharmaceutical Preparations

• Patient Login
• Partner Login
• Become A Member
• Search Clinical Trials
• About Clinical Trials
• Virtual Clinical Trials

Latest Blog Posts

Services for research sites.

• Study Listings
• Clinical Ad Network™
• Patient Direct Mail Alerts
• Create Partner Account

National Recruitment Services

• Multicenter Study Listings
• Digital Marketing Strategies
• Site Identification Services
• Direct to Patient Advertising

News And Information

• Case Studies
• Patient Recruitment Insider Blog
• For Research Sites
• Study Screening Websites

Clinical Trials in Moscow, Arkansas

• Search Results

Enter your email to receive custom alerts for new clinical trials in Moscow, Arkansas

Top searches.

• Lupus (SLE)
• Scleroderma
• Ulcerative Colitis
• Alzheimer's Disease
• Endometriosis

Search Results from C linical C onnection

© 1998-2024 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides information on clinical trials and other research opportunities worldwide.

ClinicalConnection.com does not conduct or endorse this research. Please consult your physician before participating.

• Exploring the Microbiome: Gut Health, Probiotics and Clinical Trials
• Nutrition and Clinical Trials: Latest Clinical Research on Diet's Role in Disease
• Personalized Medicine: The Power of Genetics in Clinical Trials
• Depression Clinical Trials Near Me: Current Research and How to Participate

Useful Links

1998-2024 © All Rights Reserved. Privacy Policy | Terms of Service

VitaMed Research

Leading the way in pain management and neuroscience research.

Our accomplished team of physicians and research specialists have over 50 years of combined experience and are endlessly devoted to producing superior and quality clinical research.  View our work .

Pain Studies

Device trials, stem cell research, we have a strong team of double board certified physicians at the principal investigator and/or the sub-investigator level..

Our physicians and staff are dedicated to advancing the field of medicine by participating in cutting edge clinical trials. All our physicians have the experience needed to provide quality research data.

The Moscow Department of Clinical Research processed 78 applications for drug trials over two years

21 May 2024

A single center for supporting clinical research (CT) has been operating in Moscow for two years now – the Department of Clinical Research of the Moscow Center for Innovative Technologies in Healthcare. During this period of time, the department accepted and processed 78 applications for drug research in 16 therapeutic areas received from 15 pharmaceutical companies. All applications were accepted and the companies received full support for them. This was reported by the ANO “Moscow Center for Innovative Technologies in Health Care”.

The most common therapeutic areas: oncology, hematology, immunoprophylaxis, rheumatology, endocrinology and orphan diseases. Studies of the drug commissioned by companies are carried out in leading clinics in Moscow. This is the Loginov Moscow Clinical Scientific Center, Moscow City Oncology Hospital No 62, City Clinical Hospital №1 named after N.I. Pirogov, the Kommunarka Moscow Multidisciplinary Clinical Center (MMCC), City Clinical Hospital No. 15 named after O.M. Filatov.

“Moscow plays a significant role in the rapid development of domestic biotechnologies. Since the beginning of this year alone, 12 applications from 5 pharmaceutical companies have been processed for organizational support for research in the field of oncology, rheumatology and orphan diseases, and financial support has been provided for the development of 5 unique drugs aimed at treating diseases. approved in the field of oncology, neurology and rheumatology,” said Anastasia Rakova, Deputy Mayor of Moscow in the Moscow Government for Social Development.

NovaMedica is expanding its portfolio of drugs for the treatment of diseases of the central nervous system

16 May 2024

NovaMedica team participates in the Russian Pharmaceutical Forum in St. Petersburg

14 May 2024

NovaMedica experts spoke to participants of GxP-Fest 2024 about career opportunities in the pharmaceutical industry

27 April 2024

Media Center

Cell therapy could help curb progression of heart failure

20 May 2024

China may find various medicines from the Gamaleya Center interesting

The number of conducted clinical trials in Russia is growing

17 May 2024

• My View My View
• Following Following
• Saved Saved

GSK to supply essential medicines to Russia, halt clinical trials

• Medium Text

Sign up here.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips and Vinay Dwivedi

Our Standards: The Thomson Reuters Trust Principles. New Tab , opens new tab

Business Chevron

Dollar steady as Fed urges patience; kiwi jumps on hawkish RBNZ outlook

The dollar was steady against a handful of peers on Wednesday, as the market assessed calls for patience from Federal Reserve officials and awaited the publication of Fed minutes for more insight on the central bank's path.

Russia Extends Pre-Trial Detention of Crocus Attack Suspects

A Moscow court ruled Thursday to extend the pre-trial detention of eight men accused of organizing and carrying out the deadly Crocus City Hall concert attack in March.

Law enforcement agents arrested four gunmen the day after the March 22 attack, which left 145 people dead and hundreds more wounded. A total of 11 people were eventually arrested in connection with the deadly shooting, which was claimed by Islamic State affiliate ISIS-K.

Moscow’s Basmanny District Court ruled in separate decisions on Thursday to extend the detention of Muhammadsobir Faizov , Dalerjon Mirzoyev , Saidakrami Rachabalizoda ,   Shamsidin Fariduni, Yakubjoni Yusufzoda, Dzhumokhon Kurbonov, Muhammad Zoir Sharipzoda, and Nazrimada Lutfulloi until Aug. 22.

In a video shared by the Moscow court system,  one of the suspected gunmen, Rachabalizoda, could be seen sitting inside a defendant’s box with part of his right ear cut off, seeming to corroborate previous claims that he was tortured by Russian law enforcement agents.

Another suspected gunman, Faizov,  was brought into the courtroom in a wheelchair and did not appear fully — if at all — conscious. 

The four suspected gunmen, who are all Tajik nationals, previously showed signs of having been tortured, sparking protests from Tajikistan, a Moscow ally in Central Asia that is a source of many of Russia ’s migrant workers.

At Thursday’s hearings, journalists were asked to leave  the courtroom, according to the independent news website Mediazona.

Moscow has blamed radical Islamists, Ukraine, and the West for the Crocus City Hall attack, the deadliest in Russia since the 2004 Beslan school siege, which resulted in the killing of more than 300 people.

Russia ’ s Investigative Committee has claimed it has evidence that “Ukrainian nationalists” were ultimately behind the attack and financed the gunmen with cryptocurrency payments. However, it has yet to bring forward evidence to back the allegations.

… we have a small favor to ask. As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $ 2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.

Remind me next month

Russia Says Found Link to Ukraine on Concert Attack Suspect’s Phone

6 Children Confirmed Killed in Crocus Attack, Official Says

‘Endless Wave of Violence’: Leading Russian Anti-Torture Activist on Concert Attack Suspects’ Treatment

Russian Terror Suspects Detained Under Guise of ‘Coronavirus Test’